Eledon Pharmaceuticals Inc (ELDN) - Total Assets
Based on the latest financial reports, Eledon Pharmaceuticals Inc (ELDN) holds total assets worth $237.60 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Eledon Pharmaceuticals Inc service its debt to assess how comfortably operating cash covers total debt obligations.
Eledon Pharmaceuticals Inc - Total Assets Trend (2012–2025)
This chart illustrates how Eledon Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See ELDN book value for net asset value and shareholders' equity analysis.
Eledon Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Eledon Pharmaceuticals Inc's total assets of $237.60 Million consist of 57.1% current assets and 42.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.6% |
| Accounts Receivable | $514.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $32.39 Million | 13.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Eledon Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Eledon Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eledon Pharmaceuticals Inc's current assets represent 57.1% of total assets in 2025, a decrease from 99.7% in 2012.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2025, down from 97.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 13.6% of total assets.
Eledon Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Eledon Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Eledon Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.40 | 12.42 | 26.21 |
| Quick Ratio | 7.40 | 12.42 | 26.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $117.34 Million | $132.15 Million | $106.03 Million |
Eledon Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Eledon Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.60 |
| Latest Market Cap to Assets Ratio | 1.13 |
| Asset Growth Rate (YoY) | 33.9% |
| Total Assets | $237.60 Million |
| Market Capitalization | $269.39 Million USD |
Valuation Analysis
Above Book Valuation: The market values Eledon Pharmaceuticals Inc's assets above their book value (1.13x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Eledon Pharmaceuticals Inc's assets grew by 33.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eledon Pharmaceuticals Inc (2012–2025)
The table below shows the annual total assets of Eledon Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $237.60 Million | +33.93% |
| 2024-12-31 | $177.41 Million | +40.92% |
| 2023-12-31 | $125.89 Million | +35.67% |
| 2022-12-31 | $92.79 Million | -45.59% |
| 2021-12-31 | $170.55 Million | -13.51% |
| 2020-12-31 | $197.19 Million | +1703.91% |
| 2019-12-31 | $10.93 Million | -35.80% |
| 2018-12-31 | $17.03 Million | -18.50% |
| 2017-12-31 | $20.89 Million | -29.80% |
| 2016-12-31 | $29.76 Million | -56.22% |
| 2015-12-31 | $67.97 Million | -36.91% |
| 2014-12-31 | $107.74 Million | +233.71% |
| 2013-12-31 | $32.29 Million | +169.91% |
| 2012-12-31 | $11.96 Million | -- |
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for C… Read more